Acute Rejection of Renal Transplant, Donor Specific Antibodies, Kidney Disease, End-Stage
Conditions
Keywords
Renal Transplant, Donor Specific Antibodies, African American, Acute Rejection of Renal Transplant, Kidney Transplant, End Stage Renal Disease
Brief summary
In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection (AR), donor specific antibodies (DSA), and graft failure. Envarsus Extended-Release (XR)® (ENV) is a novel extended-release formulation of tacrolimus with a favorable pharmacokinetic profile, even in the setting of CYP3A5\*1 allele (rapid metabolizers). The investigator will evaluate the safety and efficacy of early dose escalation with ENV in AA recipients. The study hypothesis is that higher tacrolimus target concentrations may be achieved without typical dose-limiting toxicities, and this may ultimately result in lower incidence of early AR, DSA, and graft loss.
Detailed description
Phase 4 (post-marketing) De novo African American living or deceased donor renal transplant recipients 18 to 65 years of age Number of subjects to be enrolled: 60 All patients will receive standard induction immunosuppression according to institution protocol. Within one week of transplantation, all patients will be converted from immediate-release tacrolimus (TAC) to extended-release tacrolimus (ENV) at 20% reduction in total daily dosage. Patients will be randomized to low-, moderate-, or high-intensity ENV groups, stratified by peak panel reactive antibody (pPRA) greater than or equal to 75%. Target tacrolimus trough concentrations for the first month post-transplant will be 8-10 ng/mL in low-intensity group, 10-12 ng/mL in moderate-intensity group, and 12-14 ng/mL in high-intensity group; likewise from month 1-3 post-transplant, target trough concentrations will be 6-8 ng/mL, 8-10 ng/mL, and 10-12 ng/mL, respectively. Subjects experiencing dose-limiting adverse events (AEs) will be de-escalated as warranted. Following month 3, all patients will be maintained on ENV at target tacrolimus trough concentrations according to institution protocol. Additional maintenance immunosuppression will consist of mycophenolate mofetil (MMF) at a goal dose of 2000 mg daily along with an oral prednisone taper to 5-10 mg daily by the end of month 1. All patients will be followed for 6 months post-transplant.
Interventions
DRUGEnvarsus XR
tacrolimus, extended-release tablets, a calcineurin inhibitor
Sponsors
Veloxis Pharmaceuticals
The Methodist Hospital Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Parallel Group - Dose Escalation with 2 groups stratified by pPRA \<75% and \>75% and then randomized into 3 Intensity Arms (Low, Moderate and High) based on dosing of Envarsus XR.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* • Primary live donor or deceased donor renal allograft * African American patients aged 18 to 65 years * Ability to take oral medications * Not currently on medications known to significantly interfere with tacrolimus metabolism, e.g. strong CYP3A4 inducers or inhibitors including but not limited to rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, protease inhibitors, azole antifungal (voriconazole, itraconazole, posaconazole, ketoconazole) o Note: All patients will be discharged on clotrimazole 10 mg three times daily for one month for thrush prophylaxis, a known mild-to-moderate CYP3A4 inhibitor * Female subjects of childbearing potential: * Not current pregnant * Agree not to try to become pregnant during the study period * Agree to consistently use two forms of highly effective birth control throughout the study period * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study
Exclusion criteria
* • Presence of a positive T- or B-cell flow cytometry allogeneic crossmatch * Presence of pre-formed anti-human leukocyte antigen (HLA) donor-specific antibodies (DSAs) * Recipient of an ABO-incompatible organ * Receipt of a multi-organ or dual kidney transplant * Receipt of pediatric en bloc deceased donor kidneys * Receipt of deceased donor kidney with a kidney donor profile index (KDPI) greater than or equal to 85% * Has undergone desensitization, or received antibody removal, anti-B-cell, or anti-plasma cell therapy in the 90 days preceding the transplant * Planned initiation of antibody removal (i.e. plasmapheresis) within 7 days of the transplant procedure * Positive test for latent tuberculosis (TB) and has not previously received adequate anti-microbial therapy or would require TB prophylaxis after transplant * Uncontrolled concomitant infection that would not allow for targeting escalated tacrolimus trough concentrations, as deemed by prescriber * Known infection or seropositivity for hepatitis B virus (HBV, defined by positive HBsAg, anti-HBcAg, or positive viral load) or hepatitis C virus (HCV) with active viral load * Current malignancy * Use of an investigational study in the 30 days prior to the transplant procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants reaching the composite endpoint | 6 months | Composite endpoint of freedom from all of the following: i) biopsy-proven T-cell mediated rejection Banff Grade ≥1A, ii) antibody-mediated rejection, iii) de novo DSA, or iv) immune-mediated graft loss. The endpoint is a binary endpoint (Yes or No) of the composite of all 4 potential outcomes. The presence of any one of the four possible outcomes will be counted as a No for the binary endpoint (no freedom from the composite endpoint). The absence of all 4 possible outcomes will be counted as Yes for freedom from all of the possible outcomes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects experiencing neurotoxicity during the study | 6 months | Clinical intolerability including headache or significant tremors that resolve with reduction of the dose of Envarsus |
| Proportion of subjects experiencing infectious complications during the study | 6 months | Participants requiring extended (\>2 weeks) reduction in dose of Envarsus due to BK-polyomavirus or cytomegalovirus viral loads at 1, 3, and 6 months post-transplant |
| Proportion of subjects experiencing nephrotoxicity during the study | 6 months | Increase in serum creatinine of ≥0.3mg/dL |
| Difference in immunosuppressant side effects between enrolled subjects | 6 months | Assessed using the Immunosuppressant Side Effects Instrument - The Memphis Survey questionnaire |
| Enrolled subject overall survival and Graft survival at 6 months | 6 months | Freedom from death and from graft loss at 6 months |
| Difference in estimated glomerular filtration rate at 1, 3, and 6 months between groups of enrolled subjects | 6 months | Assessed as the Chronic Kidney Disease - Epidemiology Collaboration equation |
Outcome results
None listed